Urogen Pharma (NASDAQ:URGN) CFO Sells 2,202 Shares of Stock

Urogen Pharma (NASDAQ:URGN) CFO Chris Degnan sold 2,202 shares of Urogen Pharma stock in a transaction on Thursday, October 8th. The shares were sold at an average price of $36.69, for a total transaction of $80,791.38. Following the completion of the sale, the chief financial officer owned 4,561 shares in the company, valued at approximately $167,343.09. This represents a 32.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Urogen Pharma Stock Performance

Shares of URGN traded up $0.53 during midday trading on Friday, hitting $37.51. 477,184 shares of the company traded hands, compared to its average volume of 807,435. The stock has a market cap of $1.83 billion, a price-to-earnings ratio of -18.88 and a beta of 1.57. The firm has a 50 day moving average of $43.85 and a 200-day moving average of $34.58. Urogen Pharma has a 52 week low of $15.86 and a 52 week high of $50.81.

Urogen Pharma (NASDAQ:URGN) last issued its earnings results on Wednesday, August 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The firm had revenue of $72.46 million during the quarter, compared to analysts’ expectations of $63.55 million. Sell-side analysts predict that Urogen Pharma will post -0.2 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on URGN shares. Jefferies Financial Group reaffirmed a “buy” rating and set a $56.00 price objective on shares of Urogen Pharma in a report on Thursday, September 10th. Guggenheim boosted their price target on shares of Urogen Pharma from $42.00 to $58.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Oppenheimer upped their price target on shares of Urogen Pharma from $40.00 to $50.00 and gave the company an “outperform” rating in a research note on Thursday, July 16th. The Goldman Sachs Group reiterated a “neutral” rating and set a $44.00 price objective on shares of Urogen Pharma in a research report on Wednesday, July 15th. Finally, UBS Group reissued a “buy” rating on shares of Urogen Pharma in a research note on Thursday, July 9th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $52.38.

Institutional Trading of Urogen Pharma

A number of hedge funds have recently added to or reduced their stakes in the company. Partners Capital Investment Group LLP bought a new stake in shares of Urogen Pharma in the 2nd quarter worth about $566,000. Legal & General Group Plc acquired a new position in Urogen Pharma in the second quarter worth $1,319,000. California State Teachers Retirement System grew its holdings in shares of Urogen Pharma by 1,605.5% during the first quarter. California State Teachers Retirement System now owns 38,750 shares of the company’s stock worth $697,000 after purchasing an additional 36,478 shares during the last quarter. Rice Hall James & Associates LLC acquired a new stake in shares of Urogen Pharma in the second quarter valued at $11,064,000. Finally, Deutsche Bank AG bought a new stake in Urogen Pharma during the 2nd quarter worth about $1,897,000. 91.29% of the stock is owned by hedge funds and other institutional investors.

Urogen Pharma Company Profile

UroGen Pharma Ltd. is a biopharmaceutical company focused on developing and commercializing therapies for cancers of the urinary tract. The company’s platform is based on RTGel, a proprietary reverse-thermal hydrogel designed to retain medicines in the urinary tract and provide localized treatment while limiting systemic exposure.

UroGen’s lead commercial product is JELMYTO (mitomycin), a gel-based therapy approved by the U.S. Food and Drug Administration for the primary chemoablation of low-grade upper tract urothelial cancer in adults.